Ali is an artificial intelligence platform that automates document processing for legal professionals, utilizing natural language processing and machine learning algorithms to enhance efficiency. By reducing the time spent on document review and analysis, Ali enables lawyers to focus on higher-value tasks and improve overall productivity.

The startup develops radiopharmaceuticals that utilize proprietary imaging and therapeutic molecules to enhance the diagnosis and treatment of metastatic cancer. By targeting both solid and hematologic malignancies, the company provides healthcare professionals with differentiated treatment options that aim to extend patient survival while maintaining favorable safety profiles.

Antaios develops a novel memory technology that enhances data storage efficiency through advanced multi-level cell (MLC) architecture. This technology addresses the limitations of traditional memory systems by significantly increasing storage density and reducing power consumption, making it ideal for high-performance computing applications.

Avenzo Therapeutics is developing targeted oncology therapies that utilize novel drug delivery systems to improve the efficacy of cancer treatments. The company focuses on addressing the limitations of current therapies by advancing a pipeline of potentially best-in-class options for patients with serious diseases.

BARO operates a fashion rental marketplace enabling women to access luxury apparel at a reduced cost. Users can also generate income by lending their own high-end clothing items to others on the platform. This service promotes affordability and sustainability within the luxury fashion consumption model.

Cardurion is developing therapeutics targeting PDE9 and CaMKII pathways to treat heart failure and various cardiovascular diseases. Their approach aims to provide effective treatment options for chronic heart failure and rare arrhythmias, addressing significant unmet medical needs in cardiovascular care.

Curamir Therapeutics develops miRNA-based therapeutics targeting cancer by utilizing microRNA modulation to inhibit tumor growth and metastasis. This approach aims to improve treatment efficacy and reduce side effects compared to traditional therapies.

Eccogene is a clinical stage biopharmaceutical company developing small molecule therapeutics for chronic cardiometabolic and inflammatory diseases, utilizing its expertise in translational research and small molecule design. The company aims to provide safer and more effective oral therapies that enhance treatment options for conditions such as obesity and type 2 diabetes.

Ensoma develops one-time, off-the-shelf, in vivo treatments that utilize advanced hematopoietic stem cell engineering to precisely modify cells within the hematopoietic system. This technology aims to provide durable cures for genetic, immune, and oncological diseases by addressing the limitations of traditional therapies that often require multiple treatments.

Exsilio develops genomic medicines that utilize lipid nanoparticles to deliver therapeutic genes into safe harbors within DNA, targeting genetic diseases, cancer, and autoimmune conditions. This approach enables precise gene insertion through RNA intermediate templates, providing a durable and safe treatment option for a wide range of diseases.

Imperative Care provides a cloud‑based, HIPAA‑compliant platform that aggregates patient data from multiple EHR systems into a single, unified view. It enables real‑time clinical alerts, automated workflow tasks, and customizable analytics dashboards to improve care coordination and reduce administrative overhead for hospitals and large health systems.

Instylla develops next-generation liquid embolics specifically designed for interventional radiology, targeting applications in interventional oncology and peripheral hemostasis. Their technology provides a precise and effective solution for occluding blood vessels, enhancing treatment outcomes for patients with hypervascular tumors.

The startup specializes in the development of native IgG-like bispecific antibodies for drug discovery in immuno-oncology, enhancing their drug-like properties to improve therapeutic efficacy. This approach enables faster access to novel treatments for patients facing cancer, addressing the slow progression of drug development in this critical area.

Re is an on‑chain reinsurance protocol that tokenizes real reinsurance treaties, issuing fully collateralized tokens backed by verified insurance premiums. The platform provides institutional investors and insurers with regulated, transparent access to the $800B+ reinsurance market, delivering 8‑16% annual yields that are largely uncorrelated with traditional assets while maintaining defined risk limits and underwriting discipline.

Rejoni develops risk mitigation solutions for gynecological procedures by utilizing advanced data analytics and predictive modeling to identify potential complications. Their technology aims to reduce both immediate and long-term health risks for patients undergoing these procedures.

Rentiva is a peer-to-peer car rental platform that connects vehicle owners with renters, ensuring all transactions are secured through Allianz Insurance and verified user profiles. The service addresses the need for affordable and convenient vehicle access by offering a wide selection of cars for daily, weekly, or monthly rentals, all backed by real-time support and roadside assistance.

Rgenta Therapeutics develops oral, small-molecule RNA-targeting medicines aimed at treating previously incurable oncology and neurological disorders. By focusing on RNA regulation, the company addresses the challenge of drugging targets that have been difficult to reach with traditional therapies.

Develops RNA interference (RNAi) therapies targeting cardiovascular diseases to reduce significant health risks associated with these conditions. The platform focuses on first-in-class small interfering RNA (siRNA) treatments, such as SRSD107, currently in Phase 1 trials, aiming to provide safer and more effective alternatives to traditional anticoagulants.

STRM.BIO utilizes extracellular vesicles to deliver gene therapy, enhancing the efficiency and safety of treatment for patients with rare diseases. This approach aims to simplify the administration of gene therapies, making them more practical and accessible for global patient populations.

TRex Bio utilizes a human tissue-based Deep Biology Platform to map Treg behavior and identify novel therapeutics for immune-mediated diseases. By leveraging advanced sequencing and computational tools, the company aims to restore tissue homeostasis and mitigate inflammation in conditions such as cancer and fibrosis.

Truvic Medical offers a single-session mechanical thrombectomy procedure for thrombus removal, eliminating the need for thrombolytics. This method reduces treatment time and minimizes complications associated with traditional thrombolytic therapies.

Tulavi Therapeutics develops the allay™ Nerve Cap, utilizing Adaptive Hydrogel Technology to create a fully absorbable, in situ forming solution that optimizes nerve recovery. This technology specifically targets the issues of neuroma formation and adhesion in peripheral nerve repair, delivering consistent and measurable outcomes in healing.

Zenas BioPharma is developing Obexelimab, a bifunctional monoclonal antibody that targets CD19 and FcγRIIb to suppress B cell activity, which is a key factor in autoimmune diseases. The company aims to provide effective therapies for patients suffering from these conditions, addressing significant unmet medical needs in immunology.